Clinical Trial

A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.

Name: A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma. — clinical trial record (NCT07251062)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2/3

View on ClinicalTrials.gov →

Summary

This is a multicenter phase 2/3 clinical study to evaluate the efficacy and safety of SYS6010 plus SG001±5-FU/Capecitabine as first-line treatment, in patients with advanced/metastatic esophageal squamous cell carcinoma.

Trial Details

NCT Number	NCT07251062
Lead Sponsor	CSPC Megalith Biopharmaceutical Co.,Ltd.
Conditions	Esophageal Squamous Cell Carcinoma
Enrollment	737 participants
Start Date	2025-12-30
Primary Completion	2029-12-30 (estimated)
Study Completion	2030-12-30 (estimated)
Updated on ClinicalTrials.gov	2025-11-26